The availability of suzetrigine may represent a critical step in addressing the nation’s pain management crisis. While ...

Pfizer has stopped developing a once-daily pill to treat obesity after a person in a clinical trial showed signs of a possible liver injury.

Pfizer had intended to move the drug into late-stage testing, but called it quits after a patient in a clinical trial experienced a potentially drug-related liver injury. View on euronews ...

The drugmaker said it would stop studying danuglipron after a participant in one of its trials experienced a possible ...